• Crescent Biopharma approved options to purchase 11,775 ordinary shares for one non-executive employee on November 2, 2026.
• The inducement options have a 10-year term and an exercise price of $12.91 per share.
• Vesting begins with 25% on the first anniversary of the employee's start date.
• The remaining options vest in monthly installments of 1/48 of the total award, subject to continued service through applicable vesting dates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031615PRIMZONEFULLFEED9869431) on November 03, 2026, and is solely responsible for the information contained therein.